|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A combined association of ABCB1 and CYP2C19 polymorphisms with new stroke was observed.
|
30742211 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population.
|
30932939 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were marginal significant interactions between CYP2C19*2 and CYP2C19*3 allele carrier status and antiplatelet treatment regimen for the risk of recurrent stroke and composite events (P = 0.054, P = 0.051, respectively) amongst smokers, but not in non-smokers.
|
30974489 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In stratified analyses by CYP2C19 genotype and ESRS, HRs (95% CIs) of the clopidogrel-aspirin therapy for stroke recurrence were 1.00 (0.70~1.42), 0.63 (0.41~0.97), 0.62 (0.40~0.96), and 0.52 (0.31~0.88) among subgroups of LoFA carriers at low risk, LoFA carriers at high risk, LoFA noncarriers at low risk, and LoFA noncarriers at high risk, respectively, with p = 0.021 for interaction.
|
31237713 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The secondary prevention of stroke according to cytochrome P450 2C19 genotype in patients with acute large-artery atherosclerosis stroke.
|
29707143 |
2018 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study will provide the evidence of the relationship between CYP2C19 genotype and clinical efficacy and safety in stroke/TIA patients taking clopidogrel by pooling the results of individual studies.
|
29901608 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
CYP2C19 LOF carriers had higher odds of new stroke than non-carriers (10.4% versus 2.4 %, hazard ratio [HR], 5.30; 95% CI, 1.51-18.3, P = 0.009) in the lowest quintile of renal function group with eGFR < 75 ml/min/1.73 m<sup>2</sup> but not in the other four higher quintiles.
|
29520080 |
2018 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among 15 studies of 4762 patients with stroke or TIA treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at increased risk of stroke in comparison with noncarriers (12.0% versus 5.8%; risk ratio, 1.92, 95% confidence interval, 1.57-2.35; P<0.001).
|
27806998 |
2017 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To estimate the association between CYP2C19 genetic variants and clinical outcomes of clopidogrel-treated patients with minor stroke or transient ischemic attack.
|
27348249 |
2016 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
The Comparison of Triflusal and Clopidogrel Effects in Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping (MAESTRO) study will investigate the effect of antiplatelet agents based on CYP2C19 polymorphisms in secondary prevention of ischemic stroke.
|
26763917 |
2016 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
There was no association between CYP2C19 metabolizer status (EM vs. RM) and the primary composite endpoint of cardiovascular death, myocardial infarction (MI), or stroke (hazard ratio [HR]: 0.86).
|
26916483 |
2016 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study evaluated the impacts of CYP2C19 polymorphisms on stroke recurrence and other vascular events in a cohort of Chinese patients receiving clopidogrel.
|
25207801 |
2015 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
There were significant differences in recurrent stroke by CYP2C19 genotype-inferred metabolizer status in white subcortical stroke patients receiving dual antiplatelet therapy with aspirin and clopidogrel, consistent with cardiovascular studies on CYP2C19 and clopidogrel; however, the bleeding risk that led to early termination of the antiplatelet arm of the SPS3 trial does not appear to be explained by CYP2C19 genotype.
|
26019129 |
2015 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
|
25529343 |
2015 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Multivariate logistic regression analysis of risk factors for cerebral ischemic stroke and recurrent stroke respectively suggests that the CYP2C19 681AA genotype may be an independent risk factor for CIS (OR = 6.179, 95% CI: 2.285 ~ 16.708; P = 0.000) and recurrent stroke (OR = 2.305, 95% CI: 1.121 ~ 4.743; P = 0.023).
|
25030528 |
2014 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A retrospective review of all patients with stroke and transient ischemic attack (TIA) tested for the clopidogrel CYP2C19 genotype was performed, with a collection of data including race/ethnicity, CYP2C19 status, and the presence of recurrent vascular events.
|
23849748 |
2014 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, VAS-treated patients with CYP2C19 impotency were susceptible to recurrent stroke during our 54-month follow-up.
|
24330577 |
2014 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
The 2-year cumulative event rates for bleeding [*wt/*17 vs. *wt/*wt: 2 vs. 2.3%; adjusted hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.16-9.45], stent thrombosis (2 vs. 1.1%; HR, 3.98; 95% CI, 0.49-31.6) or composite of any death, and myocardial infarction or stroke (5.4 vs. 7.1%; HR, 1.37; 95% CI, 0.32-5.73) did not differ on the basis of the presence of CYP2C19*17.
|
23922007 |
2013 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CYP2C19 genotypes had significant impact on clopidogrel response and prognosis of patients with stroke.
|
23640828 |
2013 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Individuals with a CYP2C19 reduced-metabolizer genotype were estimated to have a substantial reduction in the risk of the composite primary outcome (cardiovascular death, myocardial infarction, or stroke) with prasugrel as compared with clopidogrel [relative risk (RR) 0.57; 95% confidence interval (CI) 0.39-0.83].
|
20492467 |
2010 |